Please Direct All Correspondence to Customer Number **20995**

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Tachibana et al.
App. No : 10/620,296
Filed : 15 July 2003
For : ULTRASOUND ASSEMBLY FOR USE
WITH LIGHT ACTIVATED DRUGS
Examiner : Unknown
Art Unit : 3762

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

11 May 2006

(Date)


Kyle F. Schlueter, Reg. No. 54,912


Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
- (X) Listing 12 references.
 - (X) Enclosing 10 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.



Kyle F. Schlueter
Registration No. 54,912
Attorney of Record
Customer No. 20,995
(310) 551-3450

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Tachibana et al.
App. No : 10/620,296
Filed : 15 July 2003
For : ULTRASOUND ASSEMBLY FOR USE
WITH LIGHT ACTIVATED DRUGS
Examiner : Unknown
Art Unit : 3762

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 12 references to be considered by the Examiner. Also enclosed are 10 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 11 May 06

By: Kyle F. Schlueter
Kyle F. Schlueter
Registration No. 54,912
Attorney of Record
Customer No. 20,995
(310) 551-3450

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/620,296
Filing Date	15 July 2003
First Named Inventor	Katsuro Tachibana
Art Unit	3762
Examiner	Unknown
Attorney Docket No.	EKOS.8CP3DV1C3

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,876,989	03-02-1999	Berg et al.	
	2	6,680,301	01-20-2004	Berg et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	3	WO 96/07432	03-14-1996	Berg		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	4	AKHTAR, <i>Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?</i> (J. Antimicrob Chemother. 38(2): 159-165, 1996)	
	5	ANDERSON, <i>Human gene therapy.</i> (Nature 392:25-30, 1998)	
	6	BRANCH, <i>A Good Antisense Molecule is Hard to Find,</i> (Trends in Biochem Sci 23: 45-50, 1998)	
	7	CROOKE, <i>Basic Principles of Antisense Therapeutics</i> (Springer-Verlag, Eds, New York, 1998, pgs. 1 and 4)	
	8	HO and PARKINSON, <i>Antisense Oligonucleotides as Therapeutics for Malignant Diseases,</i> (Seminars in Drug Discovery 24(2): 187-202, 1997)	
	9	ORKIN and MOTULSKY, <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,</i> (p 1-38, 12/7/1995)	
	10	ROMANO et al., <i>Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications,</i> (Stem Cells 18: 19-39, 2000)	
	11	SOMIA and VERMA, <i>Gene Therapy: Trials and Tribulations,</i> (Nature Reviews Genetics 1: 91-99, 2000)	
	12	VERMA et al., <i>Gene Therapy – promises, problems and prospects,</i> (Nature 389: 239-242, 1997)	

2556637
042606

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.